Becton, Dickinson and Company (BDX) Q2 2023 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:BDX) Q2 2023 Earnings Conference Call May 4, 2023 8:00 AM ET

Company Participants

Francesca DeMartino - Senior Vice President and Head-Investor Relations

Tom Polen - Chairman, Chief Executive Officer and President

Chris DelOrefice - Executive Vice President and Chief Financial Officer

Mike Garrison - President-Medical Segment

Rick Byrd - President of the Interventional segment

Dave Hickey - President-Life Sciences Segment

Conference Call Participants

Robbie Marcus - JPMorgan

Larry Biegelsen - Wells Fargo

Vijay Kumar - Evercore ISI

Matt Miksic - Barclays

Joanne Wuensch - Citi

Rick Wise - Stifel

Operator

Good day everyone and welcome to today’s Becton, Dickinson Q2 Fiscal Year 2023 Earnings Call. At the time, all participants are in a listen-only mode. [Operator Instructions] Please note, this call maybe recorded, and that I will be standing by should you need any assistance.

It is now my pleasure to turn today’s program over to Francesca DeMartino. Ma’am please begin.

Francesca DeMartino

Good morning, and welcome to BD's earnings call. I'm Francesca DeMartino, Senior Vice President and Head of Investor Relations. On behalf of the BD team, thank you for joining us. This call is being made available via audio webcast at bd.com. Earlier this morning, BD released its results for the second quarter of fiscal 2023. We also posted an earnings presentation that provides additional details on our business, strategy, and performance. The press release and presentation can be accessed on the IR website at investors.bd.com.

Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer, and President; and Chris DelOrefice, Executive Vice President and Chief Financial Officer. Tom will provide highlights of our performance and the continued execution of our BD 2025 Strategy. Chris will then provide additional details on our Q2 financial performance and our updated guidance for fiscal 2023.

Following the prepared remarks, Tom and Chris will be joined for Q&A by our segment Presidents, Mike Garrison, President of the Medical segment; Dave Hickey, President of the Life Sciences segment; and Rick Byrd, President of the Interventional segment.

Before we get started, I want to remind you that we will be making forward-looking statements. I encourage you to read the disclaimer in our earnings release and the disclosures in our SEC filings, which are both available on the IR website. Unless otherwise specified, all comparisons will be on a year-over-year basis versus the relevant period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted.